z-logo
Premium
New NO‐Donors with Antithrombotic and Vasodilating Activities, Part 17. Arylazoamidoximes and 3‐Arylazo‐1,2,4‐oxadiazol‐5‐ones
Author(s) -
Rehse Klaus,
Bade Stephan,
Harsdorf Angela,
Clement Bernd
Publication year - 1997
Publication title -
archiv der pharmazie
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.468
H-Index - 61
eISSN - 1521-4184
pISSN - 0365-6233
DOI - 10.1002/ardp.19973301207
Subject(s) - chemistry , nitric oxide , antithrombotic , hydrochloric acid , vasodilation , biological activity , stereochemistry , pharmacology , medicinal chemistry , organic chemistry , biochemistry , endocrinology , medicine , in vitro
Seven arylazoamidoximes ( 3 ), six phenoxycarbonyl derivatives ( 4 ), and six 1,2,4‐oxadiazol‐5‐ones ( 5 ) have been prepared and their structure and purity established by spectroscopy and elemental analysis. In the EI mass spectra ready elimination of NO from the title amidoximes was observed. A new addition reaction of 3a with hydrochloric acid to 4‐chlorophenylhydroazoamidoxime 7 is described. The compounds were tested for nitric oxide dependent biological properties, i.e. platelet aggregation, antithrombotic effects, and decrease in blood pressure. In arterioles of rats 5/19 compounds inhibited the formation of thrombi with a laser beam by ≥ 20% 2 h after oral administration of 60 mg/kg. Among these are three amidoximes ( 3a, 3e, 3f ), one phenoxycarbonyl derivative ( 4a ), and one oxadiazolone ( 5a ). With the 4‐chlorophenylazoamidoxime 3c a long lasting (24 h) decrease of blood pressure in spontaneously hypertensive rats was observed. Microsomal fractions of rat liver oxidize arylazoamidoximes and generate nitric oxide (e.g. 3a and 3b ). NO was measured by the oxyhemoglobin assay. The influence of SOD, pretreatment of the rats with dexamethasone, as well as kinetic parameters were determined. Type 3 compounds, therefore, are a new class of NO donors. Type 4 and 5 compounds function as their prodrugs.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here